HealthEx Precision Medicine is designed for C-suite and board level executives who are pioneering personalised healthcare for patients across the world.
This is a 40-person Chatham House Rule, formatted forum in which industry leaders discuss and shape the future of their sector behind closed doors. They are hollow-square formats and not your standard one-dimensional meeting format meaning all executives engage in meaningful strategic and sector debate and discussion. The forums will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole.
The 40 seats will be allocated with no fewer than 36 executives and KOLs, with the remaining seats taken by Forum Co-Hosts that may include 1 Pharma, 1 Global Advisory, 1 Law Firm, 1 CRO and / or 1 Investor. The GEO breakdown will roughly be 40 US, 50% UK and EU and 10% RoW and as we are focused on diversity, we are looking to ensure that at least 30% of the attendees are women Executives.
CEO, CFOs, CBOs and executives of companies driving precision medicine and personalised healthcare. It is not for scientists, researchers and technical job titles in precision medicine
CEOs and/or event partners put forward case studies – either success stories or current challenges and use the group as “consultants”. Each case study follows this format:
Headline – short and enticing
Nutshell – a concise statement of the issue
Background – the players, the issue, what was at stake, etc
What Was Tried? - what worked and what didn’t
Questions - clarifying questions from the group.
Review - what are you taking back with you? what will you try?
All the attendees in the room will be asked: “If you could have the answer to one question, that would fundamentally help change the way your business runs, what would it be?"
￼The questions will be scored– the highest score going to the question asked ￼by the most people, and that becoming the focus of the discussion.
Executives can explore in this session:
The Industry and Business Agenda
Expediting product development and clinical implementation of personalised medicine technologies, optimising regulation, reimbursement and market access to find routes to commercialisation
The R&D Agenda
Personalised medicine for early detection & prevention of disease, applying pharmacogenomics to address unmet medical needs beyond oncology, getting personalised medicines to market as quickly as possible
The Investment Agenda
Attracting inward investment to personalised therapeutics and the latest innovative diagnostics, what investors need to see in the space to increase appetite, how different stakeholders in the sector can work to promote a greater focus on patient-centricity and facilitate greater investment into personalised healthcare
The Future Agenda
Partnerships and collaboration models for advancing the sector, instilling the necessary culture in government and healthcare systems, big data analytics squeeze inefficiencies from the system
Are you interested in a seat at the table and would like to be considered for an invitation to attend the HealthEx World Forum?